The £1.25 million University of Oxford Isis Fund, set up by Parkwalk Advisors and Oxford University Innovation in February, has made its first investments in medical device spin-out Oxtex and in Brainomix, a start up from the Isis Software Incubator which is developing software to improve stroke diagnosis.
OBN has celebrated the best of UK life science at its annual awards ceremony, and five of the winners are Oxford University Innovation spin-outs.
The Isis MedTech Showcase held in late September revealed the breadth and depth of new healthcare technologies being developed at Oxford.
OrganOx, a late-stage medical device company focused on increasing the quality and supply of organs for transplantation, has announced that it has closed a Series D Investment round.
A University of Oxford spin-out, OxSyBio, will develop 3D printing techniques to produce tissue-like synthetic materials for wound healing and drug delivery.
Rogne Bioscience, a privately-held biotechnology company based in San Francisco Bay Area, has acquired a licence to anti-inflammatory peptides from Oxford University Innovation.
Gene therapy specialist Oxford Biomedica has raised £20m to fund its portfolio of ophthalmology, CNS and cancer treatments.
Oxford-based Immunocore has announced that its immune therapy has shown promising early signs of efficacy in a Phase I trial in advanced melanoma patients.
Phillip Campbell of Oxford Innovation Society member Milton Park talks to Immunocore’s Eva-Lotta Allan.
Oxford University Innovation spin-out Kepler Energy has been awarded £30,000 at the prestigious Shell Springboard Awards.
